Edition:
United Kingdom

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

21.03USD
14 Dec 2018
Change (% chg)

$-0.26 (-1.22%)
Prev Close
$21.29
Open
$20.90
Day's High
$21.52
Day's Low
$20.73
Volume
1,202,753
Avg. Vol
1,014,183
52-wk High
$32.20
52-wk Low
$13.43

Latest Key Developments (Source: Significant Developments)

Exelixis Reports Q2 Earnings Per Share $0.28
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 EARNINGS PER SHARE $0.28.Q2 REVENUE $186.1 MILLION VERSUS I/B/E/S VIEW $155.9 MILLION.Q2 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S.MAINTAINING ITS GUIDANCE THAT TOTAL COSTS AND OPERATING EXPENSES FOR FULL YEAR WILL BE BETWEEN $430 MILLION AND $460 MILLION.  Full Article

Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib
Thursday, 10 May 2018 

May 10 (Reuters) - Exelixis Inc ::EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL VERSUS REGORAFENIB.GENENTECH INFORMED CO COMBINATION OF ATEZOLIZUMAB AND COBIMETINIB DID NOT DELIVER IMPROVEMENT IN OVERALL SURVIVAL VERSUS REGORAFENIB.GENENTECH WILL FURTHER EXAMINE RESULTS FROM IMBLAZE370 AND PLANS TO PRESENT DATA AT AN UPCOMING MEDICAL MEETING.  Full Article

Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS.EXELIXIS INC- AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NOVEL ONCOLOGY COMPOUNDS TARGETING CASEIN KINASE 1 ALPHA.EXELIXIS INC- WILL PAY STEMSYNERGY UPFRONT PAYMENT OF $3 MILLION AND UP TO $3.5 MILLION IN INITIAL RESEARCH AND DEVELOPMENT FUNDING.EXELIXIS INC- CO WILL BE SOLELY RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS THAT ARISE FROM COLLABORATION.  Full Article

Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Exelixis Inc ::EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB.EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC.  Full Article

FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - FDA::FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC.FDA SAYS GRANTED EXELIXIS' CURRENTLY APPROVED TREATMENT OPTION BROADENED LABEL THAT NOW INCLUDES ALL ELIGIBLE PATIENTS WITH ADVANCED RCC.  Full Article

Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - APPROVAL OF CABOMETYX TABLETS EXPANDS INDICATION AND COMES WELL IN ADVANCE OF PDUFA DATE OF FEBRUARY 15, 2018.  Full Article

Exelixis reports Q3 earnings per share $0.26
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Exelixis Inc :Exelixis announces third quarter 2017 financial results and provides corporate update.Q3 earnings per share $0.26.Q3 revenue $152.5 million versus $62.2 million.Q3 revenue view $104.9 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.08 -- Thomson Reuters I/B/E/S.Exelixis Inc - ‍is updating its guidance that total costs and operating expenses for full year will be between $285 million and $295 million​.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

Ipsen and Exelixis announce Phase 2 results of CABOSUN trial
Monday, 11 Sep 2017 

Sept 10 (Reuters) - IPSEN SA ::ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.CABOZANTINIB PROVIDED STATISTICALLY SIGNIFICANT IMPROVEMENT OF PROGRESSION-FREE SURVIVAL, WITH A 52 PERCENT REDUCTION IN THE RATE OF PROGRESSION OR DEATH COMPARED TO SUNITINIB.  Full Article

Exelixis announces Independent Radiology Committee review confirms results from CABOSUN
Monday, 19 Jun 2017 

June 19 (Reuters) - Exelixis Inc :Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma.Exelixis inc - u.s. Regulatory submission remains on track for q3'17.Exelixis - cabozantinib demonstrated clinically meaningful,statistically significant reduction in rate of disease progression or death as measured by pfs.  Full Article